The Fractal Force Frequency — October 2026

Introduction

Welcome to the October edition of The Fractal Force Frequency.

This month starts with two of our own articles. One asks why great clinical data so often fails to change what busy clinicians do. The other reports back from NEXT Pharma's CX & AI conference in Vienna, where AI took most of the airtime, and the customer took very little.

For the other two sections, we looked beyond our own walls. You'll find a survey of 225 senior HCPs on what they want from pharma digital, and one line from an AI transformation article that we haven't stopped quoting since.

The thread running through it all: knowing something rarely changes behaviour. Friction, incentives and habit do.

1 | Our Latest Thinking

The Lie of "Knowledge Is Power"

Start with a question that sounds odd. If knowing better were enough to change behaviour, why do so many of us still reach for sugar at 10 pm, knowing the long-term cost? The future is abstract. The relief is right here.

Pharma engagement rests on the same assumption. When a brand has strong clinical data but prescribing doesn't move, the usual diagnosis is that clinicians haven't yet absorbed the evidence. So the answer is more frequency, a sharper visual aid, or another webinar.

Our article argues that this is the wrong diagnosis. Clinicians rarely fail to adopt a better therapy because they don't understand the science. Switching a stable patient costs time in a crowded clinic, brings back the patient's worries about side effects and dosing, and adds paperwork. Staying put costs nothing today. Clinical inertia isn't negligence. It's a way of coping.

So we suggest solving for the first ten minutes, not only the next ten years. Admit the switching friction openly. Package the implementation, not just the science. Find the short-term wins in your therapy that a clinician will feel next month. Data creates intent. Friction dictates behaviour.

Read The Lie of "Knowledge Is Power" here →

What we heard at NEXT Pharma's CX & AI conference

This week we attended NEXT Pharma's CX & AI conference in Vienna: two days and more than 20 sessions. The title promised two topics, and the agenda delivered mostly one. Two HCPs spoke on day one. Omnichannel, the word that dominated these stages a few years ago, barely came up.

Our article argues that AI is now being sold the way omnichannel was, as a shortcut to customer-centricity. It needs the same foundations, and most companies only have some of them. Several speakers said so themselves. As one of them put it, automating a broken process just carries the dysfunction forward.

The bigger risk is an arms race for attention. Every company uses AI to produce more content, and together they make the HCP's inbox worse. One junior doctor told the room he doesn't open the emails. Meanwhile, customers use AI every day, while some of our own people still ask whether they're allowed to use the approved tools.

We close with five moves that separate the companies that will benefit from AI from those that will only get faster at the old model: start from the customer problem, give the customer relationship an owner, rewrite the scorecard before the tech stack, make your knowledge machine-readable, and protect judgement.

Read our NEXT Pharma reflections here →

2 | Worth Reading

The Value Gap (Graphite Digital)

Graphite Digital , a digital experience agency for life sciences, asked 225 senior HCPs what they want from pharma digital. The sample is split evenly between the UK, Germany and the USA and was surveyed in late 2025. So two-thirds of the answers are European, but the US answers are mixed in, and the results aren't split by country.

The headline is that digital engagement is no longer the problem. 69% of HCPs engaged with a pharma company digitally in the past week. The problem is value. 65% have reduced or stopped engaging with a company after a poor digital experience, and 58% say that has happened more than once. 58% also say most pharma digital content feels repetitive or not relevant.

Graphite names three tests: relevance, utility and usability. We'd underline the first. Relevance doesn't mean a name in the greeting. It means the HCP's speciality, patient population and real clinical decisions. MSD's Yazan Iwidat, quoted in the report, says pharma personalises channels and formats but not intent. 59% of HCPs want more control over what they receive and how often.

That's the foundation problem again. You can only personalise for intent if you know where an HCP is in their clinical decision, and a brand plan can't tell you that. The same goes for consistency. 72% of HCPs notice differences between Medical and Commercial communications. One more number is worth keeping: 54% prefer to give consent through a rep they already know. The field force is still the best way into the digital relationship.

One caution. Graphite designs digital experiences, so its answer leans towards better design. We'd add that better design can't fix a plan built around brand calendars. But the findings are worth reading in full.

Read the report here →

3 | Words That Stuck

"Access isn't adoption. Training completion isn't transformation."

Amy Atwood wrote those lines in an article on AI transformation. Her test for whether a company has crossed the line is simple: is AI actually changing how people approach their work?

It took us straight back to Vienna. One speaker cited research in which 80% of people say AI has improved their personal productivity, while only 37% see a positive effect on EBIT. Another described a digital champion, one of the most willing users in the company, who explained how they used the approved tool and then asked, "I hope that's fine. Is that okay?"

Atwood's answer is practical. Put managers at the centre, because they decide whether a new habit sticks. Reward learning, because people follow what the company rewards. Be honest about how roles will change. We'd add one thing. Giving people access is the easy part. The foundations around the tool decide whether it changes anything.

Read Amy's article here →

Until next month, keep building on foundations worth building on.